CJC-1295

Research Papers and Clinical Trials

The available research on CJC-1295 comes primarily from review articles published in 2026 rather than dedicated studies of the compound itself. These reviews examine CJC-1295 within the broader context of peptide therapies and performance-enhancing substances.

Several comprehensive reviews have addressed CJC-1295 as part of the "emerging landscape of performance-enhancing peptides" that target the growth hormone-IGF1 axis. These papers, published in journals including Frontiers in Endocrinology, Sports Medicine, and International Journal of Molecular Sciences, discuss CJC-1295 alongside other peptide therapies in contexts ranging from sports medicine to aesthetic and metabolic applications.

The reviews consistently frame CJC-1295 within discussions of unapproved peptide therapies, noting the gap between limited clinical evidence and widespread patient self-administration. Multiple papers published in JBJS Reviews, The American Journal of Sports Medicine, and The Journal of Sports Medicine and Physical Fitness specifically address CJC-1295's use in athletic performance enhancement and its implications for anti-doping efforts.

Clinical Trial Evidence

Only one clinical trial appears in the available evidence: a Phase 2 study (NCT00267527) that evaluated CJC-1295 in HIV patients with visceral obesity. However, this study was terminated, and no results or sample size information is provided in the available data.

Evidence Limitations

The current evidence base is notably thin. The available literature consists entirely of review articles rather than primary research studies on CJC-1295. No completed clinical trials with published results were identified, and the single registered trial was terminated without apparent completion. This represents a significant gap between the compound's apparent use and the scientific evidence supporting its safety and efficacy.

This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare provider before considering any peptide therapy.